ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.526,70
-0,40%
S&P 500
5.651,17
0,35%
Dow Jones
40.778,96
1,41%
Euro vs US Dollar
1,08815
-0,17%
Bitcoin
64.459,91
-0,60%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AZN
DatumZeitQuelleÜberschriftSymbolFirma
01/12/202116h54Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
30/11/202113h48Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
30/11/202113h00Dow Jones NewsAstraZeneca: Lynparza Gets FDA Priority Review -- UpdateNASDAQ:AZNAstraZeneca PLC
30/11/202108h49Dow Jones NewsAstraZeneca's Lynparza Supplemental New Drug Application Granted Priority Review by FDANASDAQ:AZNAstraZeneca PLC
30/11/202104h00GlobeNewswire Inc.Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in ChinaNASDAQ:AZNAstraZeneca PLC
24/11/202101h00GlobeNewswire Inc.HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor TherapyNASDAQ:AZNAstraZeneca PLC
19/11/202116h59PR Newswire (Canada)Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewingNASDAQ:AZNAstraZeneca PLC
19/11/202115h54PR Newswire (US)Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewingNASDAQ:AZNAstraZeneca PLC
18/11/202109h15Dow Jones NewsAstraZeneca Says Trials on Covid-19 Treatment Confirm Efficacy, Long-Term PreventionNASDAQ:AZNAstraZeneca PLC
17/11/202116h57Dow Jones NewsAstraZeneca's Lokelma Gets FDA Fast-Track Designation in Patients on Chronic HemodialysisNASDAQ:AZNAstraZeneca PLC
16/11/202108h52Dow Jones NewsAstraZeneca Has Delivered 2 Billion Covid-19 Vaccine Doses So FarNASDAQ:AZNAstraZeneca PLC
15/11/202117h29Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
12/11/202115h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
12/11/202111h07Dow Jones NewsCorrection to AstraZeneca Earnings ArticleNASDAQ:AZNAstraZeneca PLC
12/11/202109h11Dow Jones NewsAstraZeneca Swung to 3Q Loss Despite Higher Revenue; Continues to Lose Money From Covid-19 VaccineNASDAQ:AZNAstraZeneca PLC
11/11/202114h35PR Newswire (Canada)International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2021NASDAQ:AZNAstraZeneca PLC
11/11/202114h35PR Newswire (US)International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2021NASDAQ:AZNAstraZeneca PLC
03/11/202113h00PR Newswire (US)Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology TherapeuticsNASDAQ:AZNAstraZeneca PLC
01/11/202117h43Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
01/11/202112h42Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
01/11/202108h47Dow Jones NewsAstraZeneca to Transfer Eklira, Duaklir Global Rights to Covis Pharma for $270 MillionNASDAQ:AZNAstraZeneca PLC
25/10/202108h46Dow Jones NewsAstraZeneca's Imfinzi-Chemotherapy Combination Improved Biliary Tract Cancer SurvivalNASDAQ:AZNAstraZeneca PLC
18/10/202115h38Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
18/10/202108h50Dow Jones NewsAstraZeneca Recommends Shareholders Reject TRC Capital Mini-Tender BidNASDAQ:AZNAstraZeneca PLC
15/10/202114h05Dow Jones NewsAstraZeneca Says Study in Liver Cancer Meets ObjectiveNASDAQ:AZNAstraZeneca PLC
15/10/202113h15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
15/10/202108h49Dow Jones NewsAstraZeneca Says Combination of Tremelimumab and Imfinzi Antibodies Boosted Liver Cancer SurvivalNASDAQ:AZNAstraZeneca PLC
12/10/202115h17Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
11/10/202108h44Dow Jones NewsAstraZeneca's AZD7442 Trial Showed Reduced Risk of Developing Severe Covid-19NASDAQ:AZNAstraZeneca PLC
08/10/202113h53Dow Jones NewsAstraZeneca's Tezepelumab Gets Orphan Drug Designation in the USNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Kürzlich von Ihnen besucht

NASDAQ
AAPL
Apple
COIN
BTCUSD
Bitcoin
AMEX
XLV
Health Care Select Sector
TG
BAYN
Bayer
NYSE
JPM
JP Morgan Chase
NYSE
MRK
Merck
TG
ALV
Allianz
DBI
TDXP
Tec DAX
NASDAQ
QQQ
Invesco QQQ Trust Series 1
DBI
MDAX
MDAX
NASDAQ
NVDA
NVIDIA
COIN
ETHUSD
Ethereum
FX
EURGBP
Euro vs Sterling
USOTC
BASFY
BASF (QX)
NASDAQ
TSLA
Tesla
CCOM
SILVER
SILVER
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten